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Bacteriophage for the Elimination of Methicillin-Resistant Staphylococcus aureus  
(MRSA) Colonization and Infection 
Angela Clem 
ABSTRACT 
 Methicillin-resistant Staphylococcus aureus (MRSA) is among the most important 
pathogens affecting the human race in our time. In spite of recent medical advances, our 
therapeutic choices for MRSA infections remain limited due to the propensity of this 
organism to develop resistance to antimicrobials. Therefore, there is a continuing need to 
develop newer methods of treating MRSA infections. 
This dissertation examines the effects of bacteriophages 88 and 92 on ten clinical 
isolates of MRSA from the central Florida area. . For the majority of the MRSA isolates, 
bacteriophages 88 and 92 were unable to induce lysis. However, bacteriophage 88 was 
found to lyse MRSA Sample 94. Reduced cytotoxicity and apoptosis due to MRSA 
Sample 94 was also observed. This protective effect was most notable in the 1:10-6 
concentration of MRSA 94 and bacteriophage 88. In addition, this effect was observable 
with both immediate inoculation of the cell culture with the MRSA concurrent with the 
bacteriophage and with bacteriophage applied one hour after initial inoculation of the 
MRSA. This effect was likely due to the increased replication of the bacteriophage in the 
actively growing bacteria found in the 1:10-6 samples. The bacteria in the 1:10-6  
 ix 
concentration were likely more able to replicate in comparison to the higher bacterial 
concentrations because of less competition between the bacteria for the limited nutrients 
in the 1:10-6 concentration. 
The long-term goal of this study is the development of a bacteriophage-containing 
ointment for the control of MRSA nasal carriage. In addition, the concept of 
bacteriophage therapy may open a new horizon in controlling infections such as those 
caused by MRSA. 
Finally, as for future studies, it would be informative to be able compare these 
results with other MRSA isolates and bacteriophages samples to examine the effects 
across a wider sample of bacteria and bacteriophages. In addition, it would be interesting 
to examine the possibility of being able to modify the bacteriophage in order to allow 
lysis of the previously resistant bacterial strains. 
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Introduction 
 
Staphylococcus aureus (Microbiology - Virulence factors and Resistance) 
 Staphylococcus aureus is a Gram-positive bacterium. It is nonmotile and 
nonsporulating. It is also coagulase positive and a mannitol fermenter [14]. Methicillin-
sensitive Staphylococcus aureus (MSSA) are ubiquitous denizens of the human skin and 
nares. S. aureus possess several intrinsic enterotoxins and exotoxins which can produce 
various clinical syndromes [15].  
At the cellular level, these enterotoxins and exotoxins can induce cellular damage. 
The microorganism itself can induce cellular apoptosis after invasion of host cells. This 
invasiveness of Staphylococcus is mediated by staphylococcal fibronectin-binding 
proteins which allow the microorganism to bind to hosts cells. In addition, these 
cytotoxic strains of S. aureus could survive within host cells by avoiding degradation by 
the endolysosomal pathway and that these cytotoxic strains could produce a greater 
bacterial load and greater lethality than noncytotoxic Staphylococcal strains [52]. 
 Methicillin-resistant S. aureus (MRSA) are more therapeutically challenging 
primarily due to their resistance to commonly used antimicrobial agents. The mecA gene 
is responsible for the increased antibiotic resistance of MRSA.  The mecA gene encodes 
for PBP2a, which is a penicillin-binding protein with low-binding affinity and which 
mediates methicillin resistance [28]. The mecA gene is chromosomally encoded, and has 
been shown by ribotyping to have integrated into at least three distinct MSSA  
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backgrounds, known as A, B, and C.  The mecA gene is polymorphic and has three types, 
I, II, and III. These types vary in (1) the number of base pairs, (2) the genetic 
organization, (3) the number of insertion sequences, and (4) the resistance determinants. 
All three of the mec types have integrated into cluster A; while, only Type II has 
integrated into cluster B and cluster C. Therefore, five distinct lineages of MRSA have 
been identified since the first MRSA strain was recognized in the United Kingdom in 
1961 [27]. 
 Two genes, known as ccrA and ccrB, have been shown to be capable of 
mobilizing mecA. These two genes are cassette chromosomal recombinases genes A and 
B. These genes are homologous to the DNA recombinases of the invertase-resolvase 
family. Even though these genes exist, the horizontal transfer of mecA is still considered 
relatively rare [28].  
MRSA Prevalence:  Global, Healthcare and Community Prevalence 
The overall prevalence rate for MRSA in Tampa Bay is difficult to determine 
because there is no mandatory reporting of MRSA in Florida. One study [97] found that 
the prevalence rate for MRSA in urgent care centers averaged 12 per 10,000 visits, 24.5 
per 10,000 visits in emergency room patients, and 158 per 10,000 hospital in-patients. 
Further, this study found that MRSA comprised 42% of the S. aureus isolates from urgent 
care centers, 52% of the S.  aureus isolates from emergency rooms, and 69% of the S.  
aureus isolates from hospital in-patients. 
Nationwide, prevalence rates may vary considerably. According to the 1990 to 
1995 National Nosocomial Infections Surveillance System (NNIS) data, 16 % of  
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hospital-acquired bacteremia was due to S. aureus [7]. Approximately 25 % of all these  
nosocomial infections from S. aureus were due to MRSA [3, 7, 88]. In recent years, 
MRSA has accounted for approximately 80 % of all S. aureus isolates reported to NNIS 
[17]. 
 There has been an increasing trend in the MRSA prevalence rate in the U.S. in the 
past 20 years. In U. S. hospitals, one literature source noted that MRSA had increased 
from 2.4 % in 1975 to 29 % in 1991 [75]. Another source indicated that MRSA has  
increased from 2 % to 39.7 % over the past two decades [101]. According to the 1994 - 
1998 NNIS data, the MRSA prevalence in selected United States intensive care units 
(ICUs) ranged from 32 to 45 % [24]. A 1995 CDC estimate indicated that 34 % of S. 
aureus isolates from nosocomial bacteremia were actually MRSA [7]. The Intensive Care 
Antimicrobial Resistance Epidemiology (Project ICARE) (1996) study found that their 
MRSA rate was 35.9% [107]. These sources indicated overall prevalence rate of 
approximately 30 % for MRSA in the early to mid-1990s in the U.S. More recent figures 
may indicate even higher prevalence levels of MRSA in this country. 
For example, some sources noted that MRSA rates in U. S. hospitals were as high 
as 40 % [90, 101]. By the end of 1998, the NNIS data were indicating the MRSA isolate 
rate was near 50 % [28]. The 1999 NNIS data indicated a higher figure of 52.3 % for the 
number of the S. aureus isolates that were identified as MRSA in participating U. S. ICUs 
[43]. 
 Globally, the MRSA prevalence rates vary greatly. In northern European 
countries such as the Netherlands prevalence rates are approximately 1 % [27, 75, 101]  
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due to very stringent patient isolation procedures. In Denmark, the MRSA rate has  
decreased dramatically from approximately 20 to 30 % down to 3 % during the past 
decade because of decreased antibiotic usage [112]. However, MRSA prevalence rates 
are about 6 % in Switzerland and the other Scandinavian countries [101]. 
  The rates of MRSA prevalence in central and southern European countries such as 
France, Spain, Italy, and Greece are around 30 to 40 % [27, 47, 75, 101]. However, some 
hospitals have high-risk units with MRSA rates as high as 90 % [75]. As for the United 
Kingdom, a British study indicated that the MRSA rates increased from 1.7 % in 1990 to 
3.8 % in 1993 to 32 % in 1997 to 34 % in 1998 [43]. 
In Japan, one source reported that the rate ranged from 50 to 70 % [6]. However, 
other sources indicated that the prevalence rate may be greater than 80 % [75, 101].  
Finally, a study indicated that MRSA isolates increased from 1 % in 1995 to 6 % 
in 1999 in Canadian hospitals [101]. The literature however did not provide any 
definitive rates for South and Central America; although, the literature did indicate that 
MRSA is also an issue in these regions of the world. 
MRSA History 
 Before antibiotics, the fatality rate from S. aureus bacteremia was approximately 
90 % [59]. In the 1940s, this rate dramatically decreased with the introduction of 
penicillin G. However, by 1942, S. aureus was already showing resistance to penicillin G. 
By 1944 to 1945, the S. aureus resistance rate for penicillin had risen to 12 % to 22 %  
[59]. This rate continued to rise until the 1960s when semisynthetic penicillins like 
methicillin and oxacillin were introduced. However, resistance was noted almost  
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immediately. By 1961, 0.04 to 0.2 % of S. aureus isolates were resistant to methicillin 
and oxacillin. Although increasing S. aureus resistance to methicillin was noted in 
Europe, Australia, and the U. S. [59], there were few MRSA isolates in the U. S. before 
1967. However, by the 1970s, there was an increase in MRSA in the U. S., especially in 
large teaching facilities. MRSA slowly spread because the mecA gene, which encodes for 
an altered penicillin-binding protein, causes low-level resistance and is not plasmid-
mediated. By the 1980s and the early 1990s, MRSA had become endemic in U. S. 
hospitals and long-term care facilities [90].  
Concurrent with the increases of MRSA acquired in the healthcare setting, there 
has also been a recently recognized phenomenon:  “community-acquired MRSA”.  
“Community-acquired MRSA” has been defined as a MRSA-positive specimen that has 
been obtained outside the hospital setting or within 2 days of hospital admission, and 
with the codicil that the patient has not been hospitalized within 2 years of the date of the 
positive specimen [81]. Community-acquired MRSA isolates, still sensitive to 
vancomycin, are usually only resistant to beta-lactam antibiotics in contrast to the 
resistance to multiple antibiotics commonly detected in healthcare-acquired MRSA 
isolates [28]. 
 Although, vancomycin is the drug of choice against MRSA, the number of S. 
aureus isolates developing resistance to vancomycin has been increasing. In the 1990s, 
vancomycin intermediate Staphylococcus aureus (VISA) (Minimum Inhibitory 
Concentration (MIC) 8 to 16 ug/mL) had emerged in Japan and the U. S. (in 1997) [88, 
103]. More recently, vancomycin resistant S. aureus (VRSA) (MIC greater or equal to   
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32 ug/mL) in the United States has been reported [89]. 
Staphylococcus aureus:  Mode of Transmission, Colonization vs. Infection 
S. aureus is a resilient bacterium that makes its appearance on healthy humans 
(skin and nasopharynx) soon after birth, and then may reappear throughout life [14]. 
Mucin appears to be critical in this colonization process [104]. During this process, there 
are interactions between the staphylococcal protein(s) and the mucin carbohydrate [104]. 
 Colonization indicates that microorganisms are present on the skin and mucous 
membranes without any clinical signs or symptoms [36]. Colonization is much more 
common than infection [28]. 
The anterior nares (nasal cavity) are the main reservoir for S. aureus [3, 14, 17, 
30, 33, 59, 77, 104] and this colonization may persist for years in 10 to 20 % of carriers 
[3]. One study indicated that other than the anterior nares, the skin can also be a primary 
reservoir for S. aureus [33].  S. aureus skin carriage occurs on the hands, axilla, 
perineum, nasopharynx, and oropharynx [3, 17, 107] in 25 % to 50 % of individuals [3].  
 Colonization in other parts of the respiratory tract and other body sites may occur 
and can result in S. aureus persistence. These other sites can provide an available source  
of S. aureus for nasal recolonization [32]. Therefore, it may be difficult to eliminate nasal 
S. aureus carriage [14] because of repeated autoinoculation. One study using multisite 
culturing (pharynx, perineum, groin, axilla) found that 16 % of carriers had negative 
anterior nares cultures, but 66 % had positive cultures of extranasal sites [105]. 
As mentioned above, nasal carriage of S. aureus may spread to the individual’s 
skin and eventually to other people [33]. The nares may be the primary reservoir for hand 
carriage [30]. Interestingly, the carriage of S. aureus in the nares approximates the hand 
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carriage [17]. According to the literature, two-thirds of chronic S. aureus carriers carry it 
on their hands at least once during the year [30]. Therefore, colonized healthcare workers 
can be a potential source of MRSA transmission in a medical facility. 
The literature varied greatly regarding the carrier rates of S. aureus. Among 
healthy adults, the carrier rates of S. aureus can range between 11 % to 50 % [28, 29, 58, 
88]. As for healthcare workers (HCWS), these rates can range from 20 % to 90 % for the 
nares and approximately 50 % on the hands [14, 17, 59]. 
 At least 10 % to 20 % of healthy people have chronic S. aureus nasal carriage and 
60 to 90 % have transient nasal carriage [31, 50, 77, 104]. Another article indicated that 
S. aureus colonizes the skin and mucous membranes in 30 to 50 % of healthy adults and 
children; although, it was not clearly defined whether this was chronic or transient 
colonization [63]. 
Among the chronically ill with such conditions as diabetes, human 
immunodeficiency virus infection, and/or chronic dialysis, 40 to 60 % of these patients  
admitted to a hospital will become S. aureus carriers [75]. Furthermore, 30 % to 41 % of 
ICU patients will become S. aureus carriers [75]. 
Colonization may be transient or persistent, possibly lasting for years [28]. One 
study observed a median duration of 3.5 years for MRSA colonization [19]. It has been 
found that Staphylococcus aureus adheres better to the nasal epithelia of carriers and 
patients with eczema [105]. A previous history of MSSA nasal colonization was noted in 
25 % of MRSA carriers and indicates that certain individuals maybe at a greater risk for 
colonization [76]. Persistent carriage is more common in children than in adults [101]. 
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Young children tend to have higher colonization rates because of frequent contact with 
respiratory secretions [28].  
A study found that 6 to 24 % of newborns are colonized by S. aureus after staying 
3 to 4 days in a well-baby nursery [59]. In the 1950 to 1960s, it was shown that infants 
with hospital-acquired S. aureus colonization could carry it for 6 to 12 months after 
discharge [19]. Furthermore, 13 to 53 % of these infants were still colonized with the 
hospital strain 6 months after being discharged, and a small proportion still had nasal or 
throat colonization 1 year after discharge [2].  
Nosocomial transmission of S. aureus occurs primarily from the hands of health 
care workers (HCWs) due to contamination by colonized and infected patients [17]. 
These infected and colonized health care workers can then serve as reservoirs and  
disseminators of S. aureus [3, 17]. Further, a recent study found that medical personnel  
are more likely to be colonized with antibiotic-resistant microorganisms, than non-
medical personnel [26].  
Approximately 20 % to >93% of patients were infected or colonized before/upon 
hospital admission and up to 25 % of patients admitted to hospitals will become nasal S. 
aureus carriers [19, 47, 48, 76, 105]. Finally, patients with MRSA nasal colonization 
undetected by clinical culture may account for up to 1/3 of all patients with MRSA in a 
hospital at any given time [19]. Therefore, these patients may be inadvertent 
disseminators of MRSA to health care workers and to other patients. 
Colonization Can Lead to Infection 
 There are numerous factors that are associated with MRSA infection. First, nasal 
colonization increases the risk of S. aureus skin infections [76, 77], and infections after 
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surgical procedures [3]. Next, any conditions that compromise (or potentially 
compromise) the body’s immune status such as invasive surgical procedures [3, 19, 47, 
50, 104], severe underlying conditions/ immunocompromised [17, 50, 76], elderly status 
[17, 50, 76], invasive devices (intravenous catheters, prosthetics, mechanical ventilation, 
tracheostomy) [3, 28, 50, 76], dermatological conditions (S. aureus skin infections, burns, 
desquamating skin disorders, pressure ulcers, chronic skin lesions) [39], and frequent 
needle use (diabetes, hemodialysis, peritoneal dialysis, IV drug use, allergy shots) [3, 28, 
30, 47, 50, 76, 77,104] increased the risk of colonization and potential infection.  
Furthermore, the use of antibiotics in the recent past [3, 19, 39, 50], currently 
[76], or in combinations [76] increases the risk of colonization and infection. In addition,  
the use of ciprofloxacin and other fluoroquinolones greatly increases this risk. Sub-MIC  
(minimum inhibitory concentration) levels of ciprofloxacin increase the adhesion of 
quinolone-resistant MRSA [63]; and, fluoroquinolones allow increased MRSA adhesion 
and carriage [43] as well as directly enhancing the expression of high-level oxacillin-
resistant S. aureus in vitro [63]. 
Further, potential contact with a colonized or infected patient [19] may also 
increase this risk of colonization and infection. Therefore, this is a risk factor for health 
care workers [28, 50] and for those individuals with a history of hospitalizations within 
the past 12 months [19], current hospitalization [46], frequent (hospitalizations) [39, 47], 
prolonged hospital stays [3, 14, 19, 50, 76], and high-risk hospital areas (including the 
ICU, dermatology wards, burn unit [3, 14, 19, 39, 50, 76]. 
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Nosocomial Infection 
 According to the 1979 - 1995 NNIS data, S. aureus accounted for up to 13 % of 
all isolates from nosocomial infection [104].  MRSA colonization represents a much 
greater risk for bacteremia than MSSA colonization [7, 76]. At least 30 % of inpatients, 
who become colonized with MRSA, will develop a severe infection (such as pneumonia, 
bacteremia, and/or a wound infection) [75]. 
Among ICU patients, S. aureus nasal carriers are at a greater risk for S. aureus 
bacteremia than noncarriers [76]. Also, one-third to two-thirds of colonized ICU patients 
will ultimately develop an nosocomial MRSA infection [14]. Further, preoperative 
patients with nasal S. aureus carriage are more likely to develop a surgical site infection 
[3, 48]. In those individuals with head trauma, S. aureus nasal carriers were more likely  
to develop S. aureus pneumonia than noncarriers [3]. As for skin colonization, heavy  
colonization of the skin at the insertion site is the primary predictor of catheter-related 
infections for short-term catheters [3]. Hemodialysis patients with S. aureus skin 
colonization are at a six-fold increase for vascular-access device bacteremia compared to 
noncarriers [3].  
Current Guidelines for Infection Control 
 Although the recommendations in the literature were relatively comparable, there 
were minor differences between sources. The literature emphasized that the focus should  
be on the identification of the pathogen source and its eradication [14]. Barrier (contact) 
precautions are preferred over Standard precautions to prevent the spread by colonized 
patients [43]. However, the Centers for Disease Control (CDC) indicated that the 
Standard precautions (including hand washing, gloving, masking, gowning, appropriate 
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device usage, and appropriate laundry handling) are usually sufficient unless it is 
determined that the infection is of “special clinical or epidemiological significance” [24]. 
According to the CDC recommendations, only in these “instances” should Contact 
precautions be considered. 
Further, although one study indicated that swabs of skin lesions provide the best 
indicator of MRSA presence [49], another study indicated that active surveillance is more 
cost effective than personnel culture surveys [17]. Healthcare workers should be 
restricted from patient care activities if the worker(s) has draining S. aureus skin lesions 
until after antibiotic treatment [16]. However, no work restriction or antibiotic treatment 
need be given for S. aureus carriers unless there is an epidemiological link to an outbreak 
[17, 23]. 
Elimination of S. aureus nasal colonization may decrease S. aureus infections, 
and thus can be cost effective. For example, one study found that the mean excess 
medical and total costs attributable to nosocomial MRSA infection were approximately $ 
3500 and $ 9275 respectively, while the cost of the control measures to stop an outbreak 
were less than 10 % of the cost of treating the infection [27].  
Mupirocin  
 Mupirocin (Pseudomonic acid A) is a topical antibiotic produced by the 
fermentation of Pseudomonas fluorescens NCIB10586 [33, 64]. It has a unique chemical 
structure that is active in vitro primarily against Gram-positive organisms [33]. Although, 
mupirocin is highly active against S. aureus, it is inactive against normal skin flora [14]. 
It competitively inhibits bacterial isoleucyl-tRNA synthetase thus interfering with protein 
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synthesis [60]. Its effect is primarily bacteriostatic; but, with increasing concentrations, 
its effect becomes bactericidal [33].  
The dosage is 0.5 grams to each (or one inch) to each nostril twice a day for 5 
days. However, there is no increased effect by using the ointment longer than 5 days [14]. 
The most common adverse effects are respiratory symptoms including rhinitis, nose 
erythema, swelling, burning/stinging, pruritis, and dryness [14].  
Intranasal application of mupirocin kept the nares sterile for relatively long 
periods [76]. It was found that intranasal application may also reduce surgical site 
infections and bronchopulmonary infections [108]. There was also a decreased incidence 
of S. aureus infection after cardiothoracic, general, and neurosurgery following 
mupirocin use [14]. In addition, there were decreased S. aureus infections in adults with  
long-term hemodialysis or ambulatory peritoneal dialysis with intermittent and/or 
continuous intranasal mupirocin [14]. 
 However, with heavy colonization at multiple sites and/or with skin breaks, 
intranasal mupirocin is unlikely to eliminate colonization [44, 107]. This is readily 
understandable due to the potential for autoinoculation of the recently decolonized site. It 
has also been found that it is difficult to eliminate S. aureus from chronic wounds and 
dermatological conditions [7], since skin damage (from minor lesions, eczema, psoriasis, 
foreign body insertion) actually increases the risk of nasal carriage [105]. 
Mupirocin Resistance 
 Mupirocin-resistant MRSA was first isolated from patients with long-term 
mupirocin use for skin infections [108]. Mupirocin resistance may emerge after the use of 
oral and/or topical mupirocin for S. aureus colonization eradication [7, 17, 50, 107], and 
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that inappropriate mupirocin use may result in a persistent carrier state [33]. For example, 
low-level mupirocin-resistant MRSA emerged quickly in Japan after the introduction of 
mupirocin for nasal MRSA decolonization [108]. It was also found that intranasal 
mupirocin eradicated MRSA in the nasal cavity but not in the pharynx [108]. Instead, the 
MRSA in the pharynx was transformed into low-level mupirocin-resistant MRSA (MIC 8 
ug/mL) (without an alteration in the strain after the mupirocin treatment) [108]. 
 Further, there is both low and high level resistance to mupirocin [30, 64, 108]. 
Resistance has been predominantly low-level and an infrequent occurrence. Low-level 
resistance is due to a chromosomally encoded, modified ileS gene, which codes for a  
modified isoleucyl-tRNA synthetase [3, 14, 37, 56, 108]. Low-level resistant MRSA is 
still susceptible to 2 % mupirocin usually [3, 14]. 
 In contrast, high-level resistance (MIC greater or equal to 512 mg/mL) is a 
plasmid-encoded gene, mupA (or ileS-2), which codes for a isoleucyl-tRNA synthetase 
without any affinity for mupirocin [12, 14, 44, 56, 108]. The gene, mupA, has minimal 
homology with the staphylococcal ileS gene; and, therefore, it is believed to have 
originated in another species [56]. 
Other Agents Used to Reduce Colonization 
 Before mupirocin, bacitracin was used to decrease colonization [103]. However, 
one study found variable results with bacitracin application in the anterior nares and rapid 
recolonization after the treatment ended [77]. 
Systemic agents may impact S. aureus colonization. Rifampin is considered the 
most effective systemic agent for MRSA. It eliminates nasal carriage in 79 to 95 % of 
patients; however, 57 % of health care workers became recolonized within 4 weeks after 
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treatment [14]. Furthermore, rifampin resistance develops when it is used as a single 
agent; therefore, the literature recommended that it not be used as a single agent [103].  
Treatment 
 Intravenous vancomycin is the drug of choice for MRSA [35]. However, 
resistance to vancomycin is developing. Vancomycin intermediate S. aureus (VISA)  
(MIC 8 ug/mL) appeared in Japan in 1996 [103, 89]. By June of 2002, there were eight 
cases of VISA infection confirmed in the United States; and, the first case of 
vancomycin-resistant S. aureus (VRSA) (MIC greater or equal to 32 ug/mL) was  
reported in the United States in July of 2002 [89]. Other currently available FDA 
approved antimicrobials effective against MRSA include linezolid, daptomycin, 
quinupristin/dalfopristin, and tigecycline [3, 17, 77, 80, 103].   
Phages   
 Phages are viruses that attack bacteria. There are probably more phages in the 
world than any other organism [99].  They are ubiquitous in the biosphere; and, their 
numbers are directly related to the number of bacterial hosts present.  It has been 
estimated that there are 10 6 tailed phages per milliliter of coastal seawater and an 
estimated 10 9 tailed phages per milliliter of fresh water. Furthermore, there may be as 
many as 10 30 tailed phages in the world [4].  
There are at least 12 distinct groups of phages [68]; and, each phage species is 
specific to its bacterial host. The exact morphology and genetic material (DNA or RNA)  
varies according to the phage species. The typical structure of a phage is a hollow head 
filled with phage DNA or RNA and a tunnel-like tail for injecting the genetic material 
into the bacteria [67]. However, other morphological forms of phage exist. 
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The two major types of phage are lytic and lysogenic. Lytic phages invade the 
bacterial host, rapidly replicate themselves, and then burst the host cell. In contrast, 
lysogenic phages integrate their genetic material into the host DNA. For phage therapy, 
only lytic phages are employed in order to rapidly kill the targeted microorganism [67].  
In phage therapy, specific samples of bacteriophages are given to a patient in 
order to treat an infection by a particular microorganism. The underlying assumption of 
the bacteriophage treatment is that the treatment contains a particular bacteriophage to 
which the microorganism is susceptible. 
 In phage therapy, there are also active versus passive treatments. Active 
treatments involve providing enough phage to overwhelm the infection in one initial 
dose. On the contrary, the passive method involves providing a lower dose of phage that 
eradicates the infection as the phages multiply [72]. 
 In this study, phage 92 and phage 88 were used. These two phages have been 
shown to lyse methicillin-resistant S. aureus (MRSA) [79, 84, 85, 86, 87] and are 
available from American Type Culture Collection (ATCC). These two phages are lytic 
phages belonging to the family Siphovirdiae, which includes phages containing DNA and 
having long, thin, noncontractile tails [106]. 
Phage Immunology 
  Phages will not infect animals [32]. Phages lack the ability to enter mammalian  
cells. This makes phages less effective at lysing intracellular microorganisms. However, 
in one article [22], this deficiency was circumvented by first introducing the phages into 
Mycobacterium smegmatis, a nonvirulent mycobacterium. Next, these treated 
mycobacteria were used to infect a cell culture previously infected with Mycobacterium 
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avium and Mycobacterium tuberculosis. The phages were then effective in lysing the 
infected cells. 
Although phages are unable to produce disease in animals, when phages are 
injected into them, the phages will elicit antibody production that will eventually 
inactivate the phages [32].  The main side effects of phages to humans are due to the 
liberation of bacterial toxins as the phages lyse the bacterial cells rather than due to the 
bacteriophages [54, 67]. In addition, bacteriophages can produce effects in other aspects  
of the immune system. For example, it was found that patients treated with phages had 
lower levels of neutrophils, an increased turnover of neutrophils, and a decreased ability 
of these neutrophils to engulf bacteria [111]. These effects may be due to an increased 
number of immature neutrophils in the circulation and that these effects were associated 
with a successful recovery. It has been hypothesized that this increase in the number of 
immature neutrophils is due to the destruction of the microbes by the phages which 
stimulates the release of proinflammatory cytokines that lead to neutrophil degranulation 
and lactoferrin release which in turn stimulate several cytokines including colony-
stimulating factors. These colony-stimulating factors then stimulate the release of 
neutrophil precursors from the bone marrow thus leading to an increase in the number of 
immature neutrophils [111].  
Finally, the reticulo-endothelial system normally rapidly clears the phages from 
the circulation [61]. In another study [16], the immune response to phages was examined 
in mice. Although the mice did develop IgG and IgM to the phage, there were no 
anaphylactic reactions, no alterations in body temperature, and no other adverse effects.  
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In summary, although there is a potential for antibody production with 
intravenous bacteriophage treatment, bacteriophages have not been shown to have a 
detrimental effect on human health. Instead, phage treatment has the potential to 
stimulate the production of neutrophils while concurrently eliminating susceptible 
microorganisms. 
Phage History 
In 1896, Hankins noted that existence of “anti-infectious agents” in the Ganges 
and Jumna rivers [54, 95]. He did preliminary research on the effects of these agents on 
Vibrio cholerae; however, he did not continue the research further. 
 F. W. Twort published the first account of phages in 1915. He had noticed in his 
experiments that colonies of Micrococcus had undergone a “glassy transformation” that 
was transferable to other colonies [32]. 
 In 1917, Felix d’Herelle independently discovered phages while at the Pasteur 
Institute in Paris [96]. He believed that “invisible microbes” were present in bacteria-free 
filtrates of dysentery stool samples. Emile Roux, director of the Institute, supported this 
endeavor and tested phages on avian typhosis and Shigella dysentery [96]. Experiments 
were also performed on infected sheep, bovine hemorrhagic septicemia in Indochina, and 
Pasturella multocida in water buffalos. In addition, d’Herelle successfully treated four 
patients with bubonic plague using bacteriophages [96]. 
 The first reported phage trial was in 1921 by Bruynoghe and Maisin in France 
[58, 67]. The phages were used successfully against Staphylococcus; and, the overall 
reported phage success rate was reported at 80 to 95 % [58, 67]. However, many of the 
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later studies in the 1930s to 1940s using phages for staphylococcal abscesses were 
unsuccessful because the phages were unable to enter the walled-off abscesses [96]. 
 During the 1920s to 1940s, enthusiasm overwhelmed scientific methodology in 
the experiments with phage therapy. Lytic phages, without sufficient in vitro purification, 
were tested on animals and directly in (poorly controlled) clinical trials. The most  
extensive phage trials occurred during the Bacteriophage Inquiry during the time period 
of 1927 to 1936. However, these phage trials had variable results [54]. 
Exaggerated claims were occurring during the 1930s to 1940s. For example, one 
treatment, “Enterofagos” could supposedly cure any type of diarrhea, tuberculosis, and 
mental disorders [10] as well as herpes and eczema [29]. Other studies tested phages 
against Vibrio cholerae and Shigella dysenteriae in Southeast Asia by pouring phage 
solutions into village wells [10]. 
 However, phages were also used with some success during this time period. The 
Red Army used phage preparations in the 1930s Finnish war and World War II to protect 
against dysentery and gangrene [29]. And, the British army used phages in 1935 in India 
during a cholera epidemic [29]. Also, in 1939, Igor Asheshov had good results with anti-
Vi phage against Salmonella typhimurium in mice; but, this was due to having mixed the  
phages and bacteria in vitro prior to administration to the mice [10].And, in 1943, Dubos 
and colleagues protected mice against an experimental infection with Shigella 
dysenteriae [10]. 
Phages were even licensed for sale in the United States in the 1930s by such 
companies as Parke-Davis and Lilly [95, 96].  In the 1940s, Eli Lilly produced seven  
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phage products for humans [95]. And, since 1934, phages have been used successfully at 
the Eliava Institute of Bacteriophage, Microbiology, and Virology in Tbilisi, Georgia. A 
study by the Institute reported a 90 % success rate against S. aureus, Pseudomonas 
aeruginosa, Klebsiella pneumoniae, and Escherichia coli [2]. In addition, other eastern 
European countries and the former Soviet Union also had phages available on the market 
for years [66]. 
 But, by 1941, phages were considered unreliable and being abandoned by the 
West [29]. And, in 1959 - 1960, the World Health Organization (WHO) discarded phage 
therapy due to the success of tetracycline [10]. However, in the 1970s, a WHO-sponsored 
study in Pakistan found that high dose phages seemed “equivalent to tetracycline in 
certain aspects of the clinical control of cholera” [96]. 
 By the 1980s and 1990s, renewed interest in phage therapy was occurring. In 
1982, Smith and Huggins worked with phage specific to the K-1 capsule of Escherichia 
coli. They found that the phages were generally more effective than streptomycin, 
tetracycline, ampicillin, and TMP-SMX [10].  
Phages Benefits and Challenges 
 Phages have numerous characteristics that can make them effective therapeutic  
agents. They are specific to their target, the bacterial host [54, 58, 74, 83, 95, 96]. They 
are self-replicating at the site of infection [54, 95, 74, 96] but are also self-limiting [54, 
58] because phages only multiply in response to the presence of their bacterial host [54, 
74].  
Further, there are minimal side effects [54, 74]; and, they may be useful either as  
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adjuncts to antibiotics [54] or as alternatives for when the patient had antibiotic allergies 
[54]. The literature noted that phages may also be useful for prophylaxis of certain 
diseases [54]. 
In addition, they are naturally abundant [74] and relatively inexpensive to 
propagate [54, 67]. The literature noted that it is relatively easy to select the appropriate 
phage [67, 95]. They also can not produce disease in plants and animals [96]. Finally,  
they mutate in conjunction with their bacterial hosts [74], which decrease the potential for 
resistance [58]; and, when resistance does develop, there is usually an attenuation of the 
bacterial virulence since the phage targets the virulence determinants on the bacterial 
membrane for entry [54, 67]. 
Many of the challenges to phage therapy have arisen due to methodological 
problems in the original studies. There was a lack of information on all aspects of phages 
[54, 67]. There was minimal understanding of phage specificity so phages were not 
selected for virulence against the correct host [54, 67]. And, single phage species were 
used incorrectly against multiple bacterial strains [54, 74, 95]. In addition, it is more 
effective if the pathogen is known and then the proper phage can be selected. 
Further, there were problems in the processing of the phages. Laboratories were  
unreliable [54]. Titering of the phage was not done [54]. And, after impurities were 
removed, phage viability was not determined [74]. 
In addition, considerations were not given to the effects that the body would have 
on the phages. For orally administered phages, the gastric acid was not reduced first  
and this may have inactivated the phages [54, 67]. Furthermore, immune system 
responses to the phages were not considered [54, 74, 95].  
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As mentioned previously, enthusiasm overcame scientific proof. There was 
“exaggerated claims of success” [95] without firm scientific proof of efficacy [74, 95].  
These unsubstantiated claims affected the credibility of phage therapy in the West. 
Eventually, phage therapy was relegated to second-class science in the West [83]. And,  
finally, as might be expected, bacteria developed resistance to the phage preparations 
[54].  
Recent Phage Experiments 
 In recent years, phage therapy has been used for a variety of microorganisms, 
albeit, seldom against S. aureus. Phages have been used to treat experimental infections. 
For example, one study attempted use of phages to prevent infection in rabbits with an 
enteropathogenic strain of E. coli 0103 [78]. Another study was more successful in using 
phages that attached to the K1 capsular antigen of E. coli to prevent septicemia and a 
meningitis-like infection in chickens and delayed blood bacteremia in colostrums-
deprived calves [11].  
Also, another study used E. coli O157 antigen specific phages, KH1, KH4, and 
KH5, to control E. coli O157 in vitro with affecting other strains [53]. Next,  
another study used Lactococcus garvieae phages to prevent an experimental Lactococcus 
garvieae infection in yellowtail fish. Their study found that both intraperitoneal and oral 
administration prevented infection [65]. While, another study used phage specific to 
Pseudomonas plecoglossicida which causes bacterial hemorrhagic ascites disease in  
cultured ayu fish to control an experimental infection in the fish. Even more interestingly, 
the bacteria that became resistant to the phage became less virulent (as had been 
discussed in a previous section) [70].  
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Next, the University of Florida examined Vibrio vulnificus-specific phages from 
seawater and experimented on iron-overloaded mice infected with Vibrio.  All the 
untreated mice died within 24 hours of infection; while, none of the phage treated mice  
died [74]. While, a study used a murein hydrolase from streptococcal phage C1 called 
lysine, which is specific for groups A, C, And E Streptococci. The lysine had a rapid 
lethal effect both in vivo and in vitro on Group A Streptococci [66]. Finally, another 
study successfully used phages to treat a potentially fatal vancomycin-resistant 
enterococcus infection in mice [16]. 
 Phages have also been used to treat actual infections in humans. One study used 
phages to treat septic patients [92].  Another study used phages to treat supperative 
bacterial infections [91].  A different study used phages to treat infection in cancer 
patients [109].  In a further study, phage treatment was administered from 1981 to 1986 
to 550 cases of suppurative bacterial infections due to Staphylococcus and Gram negative 
bacteria with an improvement observed in 92.4 % of the patients. They found that their  
phages were very effective in the treatment of S. aureus with a sensitivity of 95 % [110].  
 Phages have also been used experimentally to control environmental 
microorganism contamination. A review of an American Society for Microbiology  
meeting in Los Angeles indicated that phages have been used for the treatment of Vibrio  
vulnificus, anthrax, wound and burn infections, as well as meat and poultry contamination 
[98, 16]. For example, one study used phages to decrease Pseudomonas growth on beef, 
but the phages were unable to extend the retail shelf life because of the narrow specificity 
of the phages used [40]. And, a more recent study, phages were used to decrease 
Salmonella on honeydew melon slices. The levels of Salmonella were decreased by 3.5 
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logs at 5 to 10 C and by 2.5 logs at 20 C. But, they were unable to accomplish this on 
apple slices due the acidity of the apple slices [57]. 
Finally, experiment(s) have been done to overcome one of the major challenges to 
phage therapy, which is the body’s immune response to the phages. One study developed 
a “serial passage” method for the isolation of long-circulating phage strains. They used 
the serial-passage technique to select for long-circulating E. coli phage lambda mutants 
and Salmonella typhimurium phage 22 mutants [61]. 
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Hypothesis 
 Currently available antimicrobials against MRSA have innate limitations 
including emergence of resistance and side effects. Therefore, there is a need for effective 
alternatives for prophylaxis and treatment of MRSA infection.  Bacteriophage (phage) 
therapy is one such method. The ultimate goal of this project is the creation of a phage-
containing ointment that can readily be used to prevent the spread of MRSA in the 
hospital setting and in the community.   
This dissertation examines the effects of bacteriophages 88 and 92 on methicillin-
resistant Staphylococcus aureus (MRSA) isolates from the central Florida area in an 
epithelial cell culture model. It is being hypothesized that these two phages from the 
American Type Cell Culture that are specific for MRSA will be effective in eliminating 
the MRSA isolates from the cell cultures. The specific questions being asked are: (1) Will 
phages 88 and 92 be able to lyse samples of MRSA from the central Florida area? and (2) 
Will phages 88 and 92 be able to neutralize the detrimental effects of the MRSA isolate(s) 
on an epithelial cell culture? Finally, the experimental procedures for this dissertation are 
summarized in Table 1. 
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Table 1 
Flowchart of Experimental Protocol 
 
Controls (HEp-G2 + MRSA isolates)  ELISA testing (cytotoxicity and apoptosis) 
                                 
Plaque Assays (MRSA isolates + Bacteriophage samples) 
                                 
Treated (HEp-G2 + MRSA isolates + Bacteriophage samples)  ELISA testing   
                                                                                                         (cytotoxicity and  
                                                                                                          apoptosis) 
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Methods 
HEp-G2 Cell Culture 
 Samples of HEp-G2 cells were obtained from The Moffitt Research Institute of 
USF campus. The HEp-G2 cells were propagated in DMEM media (Fisher Scientific) 
containing 10 % fetal calf serum (Fisher Scientific) and 50,000 units of Penicillin-
Streptomycin (Fisher Scientific). The cells were incubated at 37oC and in a humidified 
atmosphere of 5 % carbon dioxide and ambient oxygen. The cells were being used to 
study the effects of MRSA on epithelial cells. 
MRSA Propagation and Maintenance 
 Ten isolates of methicillin-resistant Staphylococcus aureus (MRSA) were 
obtained on agar stabs from an anonymous local healthcare system. Antibiotic resistance 
of the MRSA isolates was determined by minimum inhibitory concentration (resistant to 
Oxacillin MIC >2 mcg/ml) as well as growth on Mueller Hinton agar with 4% NaCl and 
6 ug/ml Oxacillin at the local healthcare system. All ten isolates were determined to be 
resistant to Penicillin (PCN), Oxacillin (Oxa.), Cefazolin (Cef.), and Erythromycin (Ery.). 
In addition, all isolates except sample 53 were determined to be resistant to Augmentin 
(Aug.), Ciprofloxacin (Cipro.), and Levofloxacin (Levo.). Samples 51, 46, 41, 94, and 53 
were determined to be resistant to Unasyn. And, isolates 22, 77, 49, 38, and 39 were 
determined to be resistant to Clindamycin (Clind.). 
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Table 2 
 
Antibiotic Sensitivity of MRSA Samples 
 
MRSA 
Sample 
# 
PCN Oxa. Cef. Ery. Aug. Cipro. Levo. Unasyn Clind. 
41 R R R R R R R S R 
38 R R R R R R R R S 
46 R R R R R R R S R 
49 R R R R R R R R S 
51 R R R R R R R S R 
22 R R R R R R R R S 
77 R R R R R R R R S 
53 R R R R S S S S R 
94 R R R R R R R S R 
39 R R R R R R R R S 
 
 Pulse-field gel electrophoresis (PFGE) was also carried out at the anonymous 
local healthcare system in order to determine the genotypic patterns of the ten MRSA 
isolates. The patterns for these MRSA isolates can be seen in Figure 21. Although, there 
are various methods to determine both the genotypic patterns and antibiotic resistance 
patterns of Staphylococcal strains, PFGE is considered the “gold standard” for typing 
MRSA.  
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The MRSA isolates were propagated in an incubator at 37 oC in ambient oxygen 
and then maintained on Mueller-Hinton plates (Fisher Scientific) and stored at 4 oC prior 
to experimentation. Approximately 20 hours prior to experimentation, a selected sample 
from an isolated colony was inoculated into Mueller-Hinton broth (Fisher Scientific) and 
incubated in a shaker overnight at 37 oC in ambient oxygen. 
Bacteriophages 
 Vials of bacteriophages 88 and 92 were obtained from the American Type Culture 
Collection (ATCC). The bacteriophage 88 sample arrived lyophilized and bacteriophage 
92 arrived frozen from ATCC. One milliliter of Mueller-Hinton broth was added to the 
lyophilized bacteriophage 88 sample and 0.5 ml of Mueller-Hinton broth was added to 
the frozen 0.5 ml sample of bacteriophage 92. These samples were then stored at -20 oC 
in the Mueller-Hinton broth. 
Ten µl samples of each bacteriophage were applied to a soft agar overlay of 
Mueller-Hinton plates of each MRSA isolate to determine the capability of the 
bacteriophages to form plaques on each MRSA isolate. Each MRSA isolate had been 
grown for 20 hours at 37 oC with ambient oxygen.  
For each MRSA sample, the process of inoculation with each bacteriophage 
sample was replicated on three different occasions to confirm the ability of the particular 
bacteriophage to lyse the MRSA isolate. Each plate was then observed for plaque 
formation. This process of bacteriophage application was also replicated on plates of host 
MRSA identified by (and purchased from) ATCC as being specific for bacteriophage 88 
and bacteriophage 92.  
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Plaque formation on the inoculated plates was indicative of bacterial lysis and 
bacteriophage propagation. MRSA samples that showed no plaque formation were 
excluded from further study.   
Cellular DNA Fragmentation ELISA 
 The cytotoxic and apoptotic effects of each of the MRSA samples on HEp-G2 cell 
samples were examined using the Cellular DNA Fragmentation ELISA from Roche 
Molecular Biochemicals. The Cellular DNA Fragmentation ELISA provides a 
quantitative measure of cytotoxicity and apoptosis. Approximately 20 hours prior to 
experimentation, the HEp-G2 monolayer is inoculated with DMEM containing 5’-
Bromo-2’-deoxy-uridine (BrdU) (final concentration 10 µM) and incubated aerobically 
overnight at 37 oC in 5% carbon dioxide. BrdU is a non-radioactive thymidine analogue 
used by the nuclear DNA of the HEp-G2 cells as a metabolic labeling agent and that can 
be detected by monoclonal antibodies against BrdU fragments. 
The media collected from the experimental samples contains the remnants of 
cellular debris generated by the MRSA toxin damage to the HEp-G2 cells. In contrast, the 
cellular lysates from the experimental samples provide an indication of the amount of 
induced cellular death that has been generated by the bacterial invasion of the HEp-G2 
cells. 
Experimental Procedure 
 Initial testing was carried out on 24-well plates of HEp-G2 cells determine the 
effects of varying dilutions of the selected MRSA samples. The Hep-G2 cells were 
counted via microscopy. Trypan blue was used to confirm the viability of the cells. After  
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trypan blue staining, dead cells will appear blue because of the inability of the cells to 
pump the trypan blue out of the cells. Approximately five hundred thousand HEp-G2 
cells were added to each well. The HEp-G2 cells were incubated overnight for 
approximately 20 hours at 37 oC with 5 % carbon dioxide and ambient oxygen. The HEp-
G2 cells in each well were grown in 1 ml of DMEM with 10 % fetal calf serum and 
Penicillin-Streptomycin and BrdU (final concentration 10 µM) during the 20 hour 
incubation period.  
Concurrently, samples of selected MRSA isolates were incubated in Mueller-
Hinton broth at 37 oC in a shaker in ambient oxygen. After 20 hours of incubation, the 
MRSA isolates were aliquoted into 1 ml samples and pulsed centrifuged into pellets. The 
Mueller-Hinton broth was then decanted and 1 ml of DMEM (without antibiotics) was 
added to the MRSA samples. The MRSA samples were mixed into this DMEM.  
Concurrently, DMEM media was removed from the HEp-G2 monolayers; and, 
the Hep-G2 monolayers were washed with 1 ml of PBS. The PBS was decanted; and, 1 
ml of fresh DMEM without antibiotics was applied to each negative control well.  
Next, the camptothecin-treated wells had camptothecin added to DMEM (without 
antibiotics) to a final concentration of 3.4 mcg/ml. The camptothecin-treated cells were 
used as positive controls for cellular damage and induced cellular death, since 
camptothecin is a known inducer of apoptosis. 
For the MRSA treated HEp-G2 monolayers, three different dilutions of the 
MRSA were used. The MRSA had been grown overnight in Mueller-Hinton broth at     
37 oC; and, then, broth samples were aliquoted and pulse spun for the dilutions. The broth  
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was then decanted; and, one ml of DMEM was added to each sample for further dilution.   
These full-strength samples were used for the 1:1 concentrations. The dilutions used in 
the experiments were 1:1, 1:10-3, and 1:10-6 for the MRSA samples. Approximately 300 
cfu/ml of MRSA were in each 1:10-6 dilution. This was determined by the plating of 
isolates on Mueller-Hinton agar and then counting the colonies. Finally, for the positive 
controls for the assay, 1 ml of DMEM containing Triton X-100 (10% solution) was added 
to each positive control well. 
The experimental testing on these 24-well plates of inoculated HEp-G2 cells was 
carried out over a 3-hour duration. At the end of the 3-hour incubation, the cell media and 
cell lysates were removed as described by the manufacturer’s procedures for the Cellular 
DNA Fragmentation ELISA. The next steps of the ELISA were followed according the 
procedures in the Cellular DNA Fragmentation ELISA manual available online from 
Roche. 
Procedures described above were then repeated using combinations of 
bacteriophage and MRSA samples. As with the initial experimentation, the MRSA 
sample and the HEp-G2 monolayer were incubated 20 hours prior to inoculation with 10 
µl of bacteriophage.  
Finally, combinations of MRSA-phages were retested with the application of 10 
µl of bacteriophage delayed 1-hour after the MRSA application to the HEp-G2 wells. 
This delayed time duration was used compare the effects of delayed bacteriophage 
application with the results of the simultaneous phage/MRSA combinations.   
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Table 3 
Summary Table of Experimental Combinations 
 
HEpG2 + MRSA isolates 
HEpG2 + MRSA+ Bacteriophage 88 (Immediate Treatment) 
HEpG2 + MRSA+ Bacteriophage 88 (Delayed Treatment) 
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Results  
 
 
ELISA Results of HEpG2 Cells Treated with Selected MRSA Samples 
 
 These averaged results are the compiled results of three different sample sets for 
each methicillin-resistant Staphylococcus aureus sample. Due to time and resource 
limitation, these sample sets were carried out on different days then compiled into these 
results in order to provide an average result for each MRSA isolate. For each sample set, 
there are three individual samples for each experimental condition. The bars on each 
graph represent the standard error for the averaged results. 
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Methicillin-resistant Staphylococcus aureus Sample 41 
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Figure 1. MRSA Sample 41 cytotoxicity in HEpG2 cells without bacteriophage treatment 
 
In Figure 1, overall, MRSA treatment of HEpG2 cells did not induce significant 
cellular damage; however, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 41 showed the highest levels of cellular damage. The 1:10-3 sample appears to 
have had the greatest production of toxins that resulted in the cellular damage; although, 
this was not statistically significant. 
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MRSA Sample 41 Apoptosis 
No Bacteriophage Treatment
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Figure 2. MRSA Sample 41 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 2, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 41 showed the highest levels of induced cellular death. Comparable to the results 
for the media for Sample 41, it appears that the 1:10-3 concentration had the greatest 
replication of MRSA during the 3-hour experimentation. The full-strength concentration  
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of MRSA likely had less replication due to the already concentrated nature of the sample 
(i.e. reduced log-phase growth); and, the 1:10-6 concentration had insufficient bacteria to 
provide as strong an effect as the 1:10-3 concentration. 
Methicillin-resistant Staphylococcus aureus Sample 38 
 
MRSA Sample 38 Cytotoxicity 
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Figure 3. MRSA Sample 38 cytotoxicity in HEpG2 cells without bacteriophage treatment 
 
In Figure 3, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 38 showed the highest levels of cellular damage. The full-strength concentration 
possibly had less replication due to the already concentrated nature of the sample. With 
less replication, there would likely have been less toxins produced in the full-strength  
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samples. With this sample, the 1:10-6 concentration does exhibit a greater level of toxin 
damage (and thus toxin production) than the full-strength sample but less than the 1:10-3 
samples. 
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Figure 4. MRSA Sample 38 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 4, the HEpG2 samples containing 1:1 concentration of MRSA Sample 
38 showed the highest levels of induced cellular death; although, the levels of apoptosis 
were similar with both 1:10-3 and 1:10-6 concentrations of MRSA Sample 38. For this 
particular sample, it appears that the concentration of MRSA did not have a significant on 
the amount of apoptosis. 
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Methicillin-resistant Staphylococcus aureus Sample 46 
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Figure 5. MRSA Sample 46 cytotoxicity in HEpG2 cells without bacteriophage treatment 
 
In Figure 5, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 46 showed the highest levels of cellular damage. Comparable to MRSA Samples 
41 and 38, the 1:10-3 concentration had the greatest amount of toxin production and likely 
the greatest amount of MRSA replication. It is possible with the 1:10-6 concentration that 
there were insufficient bacteria to produce an effect comparable to the other two 
concentrations. 
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Figure 6. MRSA Sample 46 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 6, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 46 showed the highest levels of induced cellular death. For the 1:10-6 
concentration, it is likely that there were an insufficient number of bacteria to produce an 
effect comparable to the other two concentrations. Of all the MRSA isolates, Sample 46 
showed the highest levels of apoptosis. 
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Methicillin-resistant Staphylococcus aureus Sample 49 
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Figure 7. MRSA Sample 49 cytotoxicity in HEpG2 cells without bacteriophage treatment 
 
In Figure 7, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 49 showed the highest levels of cellular damage. Comparable to the previous 
samples, the 1:10-3 concentration had the highest level of toxin production which likely 
was concurrent with the replication of the bacteria. The 1:10-6 concentration also showed 
greater toxin production than the full-strength concentration yet less than the 1:10-3 
concentration. This effect can be explained by the likelihood that the 1:10-6 concentration  
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would have greater nutrients (than the full-strength concentration) to allow rapid 
replication yet have less initial bacteria than the 1:10-3 concentration. 
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Figure 8. MRSA Sample 49 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 8, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 49 showed the highest levels of induced cellular death. Comparable to the 
previous samples, the 1:10-3 concentration has the highest level of apoptosis which likely 
occurred concurrent with the replication of the bacteria. The 1:10-6 concentration also 
showed greater induced cell death than the full-strength concentration yet less than the  
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1:10-3 concentration. This effect can be explained by the likelihood that the 1:10-6 
concentration would have greater nutrients (than the full-strength concentration) to allow 
rapid replication yet have less initial bacteria than the 1:10-3 concentration. 
Methicillin-resistant Staphylococcus aureus Sample 51 
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Figure 9. MRSA Sample 51 cytotoxicity in HEpG2 cells without bacteriophage treatment 
 
In Figure 9, the HEpG2 samples containing 1:10-6 concentration of MRSA 
Sample 51 showed the highest levels of cellular damage. For this sample, it is likely that 
the 1:10-6 concentration had sufficient nutrients to allow rapid replication of the bacteria.  
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It is possible for this sample that the other concentrations had insufficient nutrients to 
allow as rapid a replication as the 1:10-6 concentration. 
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Figure 10. MRSA Sample 51 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 8, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 51 showed the highest levels of induced cellular death. Although the 1:10-3 
concentration for Sample 51 did not produce as much cellular damage as the 1:10-6 
concentration, the 1:10-3 was capable of producing the most apoptosis; although, these 
results were within the standard error of the 1:10-6 concentration. 
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Methicillin-resistant Staphylococcus aureus Sample 22 
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Figure 11. MRSA Sample 22 cytotoxicity in HEpG2 cells without bacteriophage 
treatment 
 
In Figure 11, the HEpG2 samples containing 1:1 concentration of MRSA Sample 
22 showed the highest levels of cellular damage; although, the 1:10-6 concentration of 
MRSA Sample 22 showed a nearly comparable level of cellular damage. For this sample, 
the full-strength concentration appeared to have sufficient nutrients to allow the greatest 
level of replication and toxin production. 
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Figure 12. MRSA Sample 22 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 12, the HEpG2 samples containing 1:1 concentration of MRSA Sample 
22 showed the highest levels of induced cellular death. Comparable to the cytotoxicity 
results, the full-strength concentration appeared to have sufficient nutrients to allow the 
greatest level of replication and toxin production. 
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Methicillin-resistant Staphylococcus aureus Sample 77 
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Figure 13. MRSA Sample 77 cytotoxicity in HEpG2 cells without bacteriophage 
treatment 
 
In Figure 13, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 77 showed the highest levels of cellular damage; although, this effect was 
comparable to the effects of the other two concentrations. It appears that the 
concentration of bacteria did not have a significant effect on toxin production. 
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Figure 14. MRSA Sample 77 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 14, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 77 showed the highest levels of induced cellular death; although, the 1:1 and 
1:10-6 concentrations of MRSA Sample 77 showed nearly comparable levels of apoptosis. 
It appears that the concentration of bacteria did not have a significant effect on induced 
cellular death. 
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Methicillin-resistant Staphylococcus aureus Sample 53 
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Figure 15. MRSA Sample 53 cytotoxicity in HEpG2 cells without bacteriophage 
treatment 
 
In Figure 15, the HEpG2 samples containing the 1:1 concentration of MRSA 
Sample 53 showed the highest levels of cellular damage. It appears that the full strength 
concentration had sufficient nutrients to allow rapid replication; and, it is likely that the 
other concentrations had insufficient bacteria to produce a comparable effect.  
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Figure 16. MRSA Sample 53 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 16, the HEpG2 samples containing the 1:1 concentration of MRSA 
Sample 53 showed the highest levels of induced cellular death. It appears that the full 
strength concentration had sufficient nutrients to allow rapid replication; and, it is likely 
that the other concentrations had insufficient bacteria to produce a comparable effect.  
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Methicillin-resistant Staphylococcus aureus Sample 94 
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Figure 17. MRSA Sample 94 cytotoxicity in HEpG2 cells without bacteriophage 
treatment 
 
In Figure 17, the HEpG2 samples containing the 1:10-6 concentration of MRSA 
Sample 94 showed the highest levels of cellular damage. For this sample, it is likely that 
the 1:10-6 concentration had sufficient nutrients to allow rapid replication of the bacteria. 
It is possible for this sample that the other concentrations had insufficient nutrients to 
allow as rapid a replication as the 1:10-6 concentration. 
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Figure 18. MRSA Sample 94 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 18, the HEpG2 samples containing the 1:10-6 concentration of MRSA 
Sample 94 showed the highest levels of induced cellular death. For this sample, it is 
likely that the 1:10-6 concentration had sufficient nutrients to allow rapid replication of 
the bacteria. It is possible for this sample that the other concentrations had insufficient 
nutrients to allow as rapid a replication as the 1:10-6 concentration. 
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Methicillin-resistant Staphylococcus aureus Sample 39 
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Figure 19. MRSA Sample 39 cytotoxicity in HEpG2 cells without bacteriophage 
treatment 
 
In Figure 19, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 39 showed the highest levels of cellular damage. Comparable to MRSA Samples 
41 and 46, the 1:10-3 concentration had the greatest amount of toxin production and likely 
the greatest amount of MRSA replication. For the 1:10-6 concentration, it is likely that 
there were an insufficient number of bacteria to produce an effect comparable to the other 
two concentrations. 
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Figure 20. MRSA Sample 39 apoptosis in HEpG2 cells without bacteriophage treatment 
 
In Figure 20, the HEpG2 samples containing 1:10-3 concentration of MRSA 
Sample 39 showed the highest levels of induced cellular death. For the 1:10-6 
concentration, it is likely that there were an insufficient number of bacteria to produce an 
effect comparable to the other two concentrations. 
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Summary of Cytotoxicity and Apoptosis Results for MRSA Samples 
 
The cytotoxicity results of the MRSA samples are summarized in Table 4; and, 
the apoptosis results of the MRSA samples are summarized in Table 5. The levels of 
cytotoxicity and apoptosis are indicated by the number of + signs: +++ (high), ++ 
(medium), and + (low). 
Table 4 
Summary Table of Cytotoxicity Results for MRSA Samples 
 
MRSA Sample # 1:1 1:10-3 1:10-6 
41 ++ +++ + 
38 + +++ ++ 
46 ++ +++ + 
49 + +++ ++ 
51 ++ + +++ 
22 +++ + ++ 
77 + +++ ++ 
53 +++ ++ + 
94 + ++ +++ 
39 ++ +++ + 
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Table 5 
Summary Table of Apoptosis Results for MRSA Samples 
 
MRSA Sample # 1:1 1:10-3 1:10-6 
41 + +++ ++ 
38 +++ ++ + 
46 ++ +++ + 
49 + +++ ++ 
51 + +++ ++ 
22 +++ + ++ 
77 ++ +++ + 
53 +++ ++ + 
94 ++ + +++ 
39 ++ +++ + 
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Bacteriophage Treated HEp-G2 Samples 
 
Table 6  
 
Bacteriophage Treatment 
 
MRSA Sample Bacteriophage 88 Plaque 
Formation 
Bacteriophage 92 Plaque 
Formation 
Sample 22 - - 
Sample 38 - - 
Sample 39 - - 
Sample 41 - - 
Sample 46 - - 
Sample 49 - - 
Sample 51 - - 
Sample 53 - - 
Sample 77 - - 
Sample 94 + - 
. 
 Each MRSA sample was tested in three separate trials carried out on different 
days with 10 µl of full-strength bacteriophage-containing Muller-Hinton media. This  
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procedure was also carried out on plates of the host MRSA specified by ATCC. Only on 
the plates of host MRSA did visible and widespread plaques form within three days. With 
the experimental MRSA isolates, plaques developed only on the plates of Sample MRSA 
94 inoculated with bacteriophage 88. This plaque formation by bacteriophage 88 on 
Sample 94 was limited and slower to develop (within seven days of bacteriophage 
inoculation). Because of this bacterial resistance to the bacteriophage, further testing with 
the bacteriophages on the 24-well plates was limited to experimentation with MRSA 
Sample 94 and bacteriophage 88.  
 
      MRSA samples  
Figure 21. Pulsed-Field Gel Electrophoresis of MRSA Samples 
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Pulsed-field gel electrophoresis (PFGE) was carried out to determine the 
genotypic patterns of each MRSA isolate. Figure 21 provides these PFGE patterns of the  
selected MRSA samples used in the experiments. Comparable patterns for the original 
host MRSA strains from the American Type Culture Collection were unavailable for 
comparison with these above PFGE patterns. MRSA Sample 94 appears to have an 
additional band (marked with an arrow) that is unique from the other MRSA samples and 
may account for the susceptibility of MRSA sample 94 to bacteriophage 88. 
Immediate Bacteriophage Treatment 
 After the completion of the ELISA testing of the HEp-G2 monolayers treated with 
the selected MRSA isolates, plaque assay testing of bacteriophages 88 and 92 was carried 
out with the MRSA isolates. From Table 6, only the combination of bacteriophage 88 and 
MRSA sample 94 showed plaque formation; therefore, only MRSA sample 94 was used 
for further experimentation. This plaque formation was minimal in comparison to the 
amount of plaque formation that occurred with the inoculation of bacteriophage 88 on its 
host MRSA. 
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Figure 22. MRSA Sample 94 cytotoxicity in HEpG2 cells with immediate bacteriophage 
treatment compared with untreated samples 
 
In Figure 22, the HEpG2 samples immediately treated with bacteriophage 88 
showed decreased levels of cellular damage. This effect appeared greatest with the 1:10-6 
concentration of MRSA Sample 94 and the 1:10-6 concentration of bacteriophage 88. 
Without treatment, the 1:10-6 treatment exhibited the greatest level of cellular damage 
which was likely indicative of the greatest bacterial replication. Because bacteriophages 
replicate in active growing cells, it is likely that their effect would be greatest in the 
samples containing the greatest number of actively replicating bacteria which would be  
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the 1:10-6 samples. This effect was seen with the 1:10-6 samples treated with the 
bacteriophages. 
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Figure 23. MRSA Sample 94 apoptosis in HEpG2 cells with immediate bacteriophage 
treatment compared with untreated samples 
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In Figure 23, the HEpG2 samples immediately treated with bacteriophage 88 
showed decreased levels of induced cell death. This effect appeared greatest with the 
1:10-6 concentration of MRSA Sample 94 and the 1:10-6 concentration of bacteriophage  
88. Without treatment, the 1:10-6 treatment exhibited the greatest level of apoptosis which 
was likely indicative of the greatest bacterial replication. Because bacteriophages 
replicate in active growing cells, it is likely that their effect would be greatest in the 
samples containing the greatest number of actively replicating bacteria which would be 
the 1:10-6 samples. This effect was seen with the 1:10-6 samples treated with the 
bacteriophages. 
 At the completion of the three hour incubation, samples of the MRSA were not 
removed from the 24-well plates and plated to determine if there was complete 
eradication of the MRSA. It is unlikely that there was complete eradication of the MRSA 
in this limited time period. The three hour incubation period was used to allow time for 
the MRSA and bacteriophage to interact within the cell culture while minimizing the 
effects of the natural apoptosis of the HEp-G2 cells due to decreasing nutrients and 
increasing cellular waste products. 
The cytotoxicity and apoptosis results for immediate bacteriophage treatment are 
summarized in Table 7. The levels of cytotoxicity and apoptosis are indicated by the 
number of + signs: +++ (high), ++ (medium), and + (low). 
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Table 7 
Summary Table of Results for MRSA Sample 94 (Immediate Bacteriophage Treatment) 
 
 1:1 1:10-3 1:10-6 
Cytotoxicity + ++ +++ 
Apoptosis ++ + +++ 
 
Statistical Results for Immediate Bacteriophage Treatment 
 
 Due to the variations between the results for the no treatment samples in 
comparison to the immediate treatment samples, the results were normalized against the 
positive controls for each sample set. For each of the three sample sets, the three results 
for the positive control were averaged. Next, each individual result for the other 
conditions (negative, camptothecin 3.4 mcg/ml, MRSA 1:1, MRSA 1:10-3, MRSA 1:10-6) 
within the sample set were normalized against the average of the three positive control 
results for that particular sample set. This process was completed for both the immediate 
treatment samples and the no treatment samples (to serve as a comparison). 
 A Tukey statistical test (alpha = 0.05, Q = 2.88849) was performed on these 
results. There was no significant difference between the treatments for cytotoxicity. In 
addition, there was no significant difference between the conditions for the cytotoxicity 
results; although, there was a significant difference (p<0.0001) between the cytotoxicity 
results for the negative controls and for the camptothecin results for the delayed treatment 
results.  
 Both a Tukey statistical test (alpha = 0.05, Q = 2.88849 for the conditions and Q = 
2.36823) and a Student’s t test (alpha = 0.05, t = 1.97658) were performed for the  
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apoptosis results. Although there was no significant difference between the conditions, 
there was a significant difference (p<0.0001) between the apoptosis results for the no 
treatment and immediate treatment groups for the negative controls and for the 
camptothecin results. 
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Figure 24. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
immediate bacteriophage treatment compared with untreated samples (The error bars 
indicate the standard deviation for each condition.). 
 
 From Figure 24, the normalized results did not indicate any significant differences 
between the no treatment and immediate treatment results; although, the MRSA 1:10-6 
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condition for the immediate does appear lower than the no treatment results. In contrast, 
the results for the other MRSA concentrations actually appear higher than the no 
treatment results. 
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Figure 25. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
immediate bacteriophage treatment compared with untreated samples (The error bars 
indicate the standard deviation for each condition.). 
 
 From Figure 25, the normalized results for both the no treatment and immediate 
treatment groups appear comparable; although, the higher concentrations of the MRSA 
appear higher in the immediate treatment groups. 
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Delayed Bacteriophage Treatment 
 
 Concurrent with the experimentation involving bacteriophage 88 applied 
simultaneously with MRSA sample 94 onto HEp-G2 monolayers, experimentation was 
carried out with MRSA sample 94 applied to the HEp-G2 monolayer but with 
bacteriophage 88 applied one hour after the initial inoculation of MRSA sample 94 onto 
the HEp-G2 monolayer. This delayed treatment with bacteriophage 88 was to determine 
if the bacteriophage would be capable of neutralizing the effects of the MRSA even with 
delayed bacteriophage treatment. 
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Figure 26. MRSA Sample 94 cytotoxicity in HEpG2 cells with one-hour delayed 
bacteriophage treatment compared with untreated samples 
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In Figure 26, the HEpG2 samples with delayed treatment with bacteriophage 88 
showed decreased levels of induced cytotoxicity. This effect appeared greatest with the 
1:10-6 concentration of MRSA Sample 94 and the 1:10-6 concentration of bacteriophage 
88. As comparable with the immediately treated samples, the 1:10-6 MRSA treatment 
(without bacteriophages) exhibited the greatest level of cellular damage which was likely 
indicative of the greatest bacterial replication. Because bacteriophages replicate in active  
growing cells, it is likely that their effect would be greatest in the samples containing the 
greatest number of actively replicating bacteria which would be the 1:10-6 samples. This 
effect was seen with the 1:10-6 samples treated with the bacteriophages. 
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MRSA Sample 94 Apoptosis 
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Figure 27. MRSA Sample 94 apoptosis in HEpG2 cells with one-hour delayed 
bacteriophage treatment compared with untreated samples 
 
In Figure 27, the HEpG2 samples with delayed treatment with bacteriophage 88 
showed decreased levels of induced cell death. This effect appeared greatest with the 
1:10-6 concentration of MRSA Sample 94 and the 1:10-6 concentration of bacteriophage  
88. As comparable with the immediately treated samples, the 1:10-6 MRSA treatment 
(without bacteriophages) exhibited the greatest level of apoptosis which was likely 
indicative of the greatest bacterial replication. Because bacteriophages replicate in active 
growing cells, it is likely that their effect would be greatest in the samples containing the  
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greatest number of actively replicating bacteria which would be the 1:10-6 samples. This 
effect was seen with the 1:10-6 samples treated with the bacteriophages. 
At the completion of the three hour incubation, samples of the MRSA were not 
removed from the 24-well plates and sampled in order to determine if there was complete 
eradication of the MRSA. It is unlikely that there was complete eradication of the MRSA 
in this limited time period. The three hour incubation period was used to allow time for 
the MRSA and bacteriophage to interact within the cell culture while minimizing the 
effects of the natural apoptosis of the HEp-G2 cells due to decreasing nutrients and 
increasing cellular waste products. 
The cytotoxicity and apoptosis results for immediate bacteriophage treatment are 
summarized in Table 8. The levels of cytotoxicity and apoptosis are indicated by the 
number of + signs: +++ (high), ++ (medium), and + (low). 
Table 8 
Summary Table of Results for MRSA Sample 94 (Delayed Bacteriophage Treatment) 
 
 1:1 1:10-3 1:10-6 
Cytotoxicity + ++ +++ 
Apoptosis ++ + +++ 
 
Statistical Results for Delayed Bacteriophage Treatment 
As with the immediate treatment samples the results were normalized against the 
positive controls for each sample set. For each of the three sample sets, the three results 
for the positive control were averaged. Next, each individual result for the other  
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conditions (negative, camptothecin 3.4 mcg/ml, MRSA 1:1, MRSA 1:10-3, MRSA 1:10-6) 
within the sample set were normalized against the average of the three positive control 
results for that particular sample set. This process was completed for both the delayed 
treatment samples and the no treatment samples (to serve as a comparison). 
A Tukey statistical test (alpha = 0.05) was performed on these results. There was 
no significant difference between the treatments for apoptosis. There was a significant 
difference (p<0.0001) between the cytotoxicity results for the negative controls and for 
the camptothecin results for the delayed treatment results.  
 Both a Tukey statistical test (alpha = 0.05) and a Student’s t test (alpha = 0.05) 
were performed for the apoptosis results. There was no significant difference between the  
apoptosis results for the no treatment and delayed treatment group results. 
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Figure 28. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
delayed bacteriophage treatment compared with untreated samples (The error bars 
indicate the standard deviation for each condition.). 
 
From Figure 28, the normalized results appear comparable for both the no 
treatment conditions and the delayed treatment conditions; although, the MRSA results 
for the delayed treatment MRSA 1:10-6 concentration appear slightly lower than for the 
no treatment condition. 
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Figure 29. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
delayed bacteriophage treatment compared with untreated samples (The error bars 
indicate the standard deviation for each condition.). 
 
 From Figure 29, the normalized results for both the no treatment and immediate 
treatment groups appear comparable; although, the higher concentrations of the MRSA 
appear higher in the delayed treatment groups. 
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Summary of Statistical Results for Immediate and Delayed Bacteriophage Treatment 
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Figure 30. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
immediate and delayed bacteriophage treatment compared with untreated samples (The 
error bars indicate the standard deviation for each condition.). 
 
From Figure 30, it appears that the normalized results for all the conditions appear 
comparable; although, both the immediate and delayed results for the MRSA 1:10-6 
concentration appear slightly lower than the no treatment results. 
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Figure 31. Normalized results of MRSA Sample 94 apoptosis in HEpG2 cells with 
immediate and delayed bacteriophage treatment compared with untreated samples (The 
error bars indicate the standard deviation for each condition.). 
 
From Figure 31, it appears that the normalized results for all the conditions appear 
comparable. There does not appear be any difference in the level of apoptosis between 
the no treatment, immediate treatment, and delayed treatment groups for the MRSA  
1:10-6 concentration. 
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Discussion 
There were two questions regarding the use of bacteriophages for the elimination 
of MRSA that were explored in these experiments. In regards to the first question, Will 
phages 88 and 92 be able to lyse samples of MRSA from the central Florida area?, put 
forth by this dissertation, bacteriophages 88 and 92 were unable to induce lysis in the 
majority of the selected MRSA samples. MRSA sample 94 was the exception. The 
susceptibility of MRSA sample 94 to bacteriophage 88 may have been due to the 
particular surface receptors on MRSA sample 94. 
The literature indicates that numerous surface proteins have been identified on S. 
aureus strains. These surface proteins include clumping factor A, clumping factor B, 
Fibronectin binding protein A, Fibronectin binding protein B, collagen adhesion, SdrC, 
SdrD, SdrE, Protein A, Methicillin resistance surface protein, phosphoglucomutase, 
multiple cell wall surface anchor proteins, 5-nucleotidase family protein, extracellular 
adherence protein, extracellular matrix and plasma binding protein, cell wall-associated 
fibronectin binding protein, fibrinogen binding-related protein, fibrinogen binding protein, 
elastin binding protein, and biofunctional autolysin. However, there was no information 
available identifying which of these particular surface proteins can be used by 
bacteriophage as receptors to enter Staphylococcal strains [38]. 
From Figure 21, the pulsed-field gel electrophoresis (PFGE) patterns of the ten 
MRSA samples were shown. MRSA sample 94 appears to have a band that is unique 
from the other MRSA samples; and, it is likely that this band accounts for the 
susceptibility of MRSA sample 94 to bacteriophage 88.  
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Although the American Type Culture Collection was contacted regarding the 
genotypic patterns of their bacteriophage hosts, the genotype patterns of the MRSA hosts 
for bacteriophages 88 and 92 were unavailable. In addition, ATCC indicated that the 
company had no information available on the effects of these two bacteriophages on 
other MRSA strains because the two bacteriophages were propagated on their particular 
host MRSA strains. 
This limited the comparison of the host MRSA genotype patterns with the 
genotype patterns of the selected MRSA isolates to determine if the particular band seen 
on the PFGE pattern on MRSA Sample 94 also occurred on the genotype pattern for the 
bacteriophage 88 host. If this particular band was shared by both MRSA isolates, it could 
indicate that this particular band is connected to the susceptibility of these two MRSA 
isolates to bacteriophage 88. Also, it may indicate that this band is linked to the particular 
receptor that allows bacteriophage 88 to invade and lyse this MRSA isolate.  
There are other potential factors that may have affected the ability of 
bacteriophages 88 and 92 to lyse the MRSA isolates. For instance, bacteriophages are 
known to be species specific in regards to their host range; however, it has also been 
noted in the literature that bacteriophages can even be strain specific for their particular 
bacterial host [1]. 
 Further, lysogenic bacteriophages may also have affected the ability of phages 88 
and 92 to lyse the MRSA isolates. Lysogenic bacteriophages are known to integrate into 
bacterial genomes and prevent infection of the same bacteria by a homologous 
bacteriophage. However, there are mutant bacteriophages, known as vir (short for 
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virulent) mutants, which can circumvent this resistance due to a lysogenic bacteriophage. 
[1] 
 Another consideration in regards to the resistance of the MRSA isolates to the 
bacteriophages 88 and 92 is that the MRSA isolates originally cultured with the 
bacteriophages 88 and 92 came from the same geographic area and time period as the 
bacteriophages. [86, 87] In addition, it should be noted that only one particular MRSA 
host was noted by ATCC for each bacteriophage rather than a selection of potential 
MRSA hosts. This would likely indicate that these were the bacterial isolates that were 
predominantly lysed by bacteriophages 88 and 92. 
Also, MRSA isolates have continued to evolve over time. There are at least eight 
different MRSA (oxacillin-resistant) lineages, known as USA100 through USA800, in 
the U.S. currently. USA100, USA200, USA500, USA600, and USA800 are typically 
found in healthcare settings. In contrast, USA300 and USA400 are more commonly 
found in community settings; and, USA700 can be found in both healthcare and 
community settings. Further, USA100 isolates are the most commonly cultured oxacillin-
resistant lineage; and, these isolates are usually multidrug resistant and include most of 
the VISA and VRSA isolates in the U.S.. USA200, USA500, and USA600 are also 
multidrug resistant and have similar PFGE patterns to epidemic strains from Europe and 
Australia. In contrast, USA300 and USA400 typically contain community-acquired 
isolates that are only resistant to beta-lactam drugs and erythromycin [60]. With this 
continued evolution, the present day MRSA isolates have varying levels of dissimilarity  
to the MRSA from previous decades as evidenced by the differential lysis patterns of the 
phage hosts versus the MRSA isolates examined in this study. 
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In regards to the second question, Will phages 88 and 92 be able to neutralize the 
detrimental effects of the MRSA isolate(s) on an epithelial cell culture?, put forth by this 
dissertation, bacteriophage 88 does appear to have had some protective effect on the 
HEp-G2 samples from the cellular damage and apoptosis that had been previously 
induced by MRSA sample 94 inoculation. This protective effect of the bacteriophages 
appeared greatest in the HEp-G2 samples containing 1:10-6 concentrations of MRSA 
sample 94 and bacteriophage 88. 
In conclusion, the effects of bacteriophage 88 on the MRSA sample 94 inoculated 
on the HEp-G2 wells does indicate that bacteriophages can provide a protective effect  
from MRSA cellular damage and apoptosis when used against susceptible MRSA strains. 
However, it has to be noted that due to the strict specificity of the bacteriophages for 
particular bacterial strains, there must be a good match between the bacteriophages and 
the bacterial strains in order to have the intended effect of bacterial destruction. For 
example, in one study [41], it was found that twelve samples of vancomycin-intermediate 
S. aureus in general had altered bacteriophage susceptibility patterns in contrast to the 
bacteriophage susceptibility patterns of their original seven vancomycin-sensitive parent 
strains; however, the particular receptor alterations that changed the bacteriophage 
susceptibility patterns were not identified. Also, this study noted that major genetic 
changes were not required for MRSA to develop into vancomycin intermediate-resistant 
S. aureus (VISA). In fact, SmaI chromosomal RFLPs could remain quite similar between 
the vancomycin-sensitive parent strains and the altered VISA strains. 
From another study, it is entirely possible to correlate antibiotic resistance 
patterns with PFGE patterns; however, antibiotic resistance patterns and PFGE patterns 
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may not be indicative of bacteriophage susceptibility patterns for Staphylococcal strains 
[46]. 
This difficulty may be overcome by using multiple bacteriophages strains against 
the particular bacterial strain. With the availability of genotypic testing for MRSA, it 
would possible to determine particular problematic MRSA strains in a community (or 
communities) that could be targeted with different bacteriophages known to lyse these 
particular MRSA strains. It may be necessary that the bacteriophages used in treatment 
would have to be in varied combinations specified by the prevailing MRSA strains in a 
particular community. However, it is highly probable that these bacteriophage 
combinations would change over time as the prevailing MRSA strains changed.  
Low doses of bacteriophage in different preparations such as ointments may 
increase in sufficient numbers when applied in the anterior nares where S. aureus is 
commonly found and may allow eradication of the targeted bacterial host. Further, from a 
recent study, it was shown that bacteriophages propagated on weakly susceptible 
bacterial strains could result in modified bacteriophages that were then capable of lysing 
the original bacterial strains [69].  
As for future studies, it would be informative to be able compare these results 
with other MRSA isolates and bacteriophages. With the change in receptors over time, it 
may be possible that other staphylococcal phages that have not previously been 
associated with the lysis of MRSA may be able to lyse some MRSA strains. 
Also, it would be useful to study the PFGE patterns of the host MRSA for 
bacteriophage 88 and bacteriophage 92. Because these host MRSA were originally 
cultured in the late 1970s, ATCC was unable to provide PFGE patterns for their MRSA 
 79 
hosts. In addition, it would be useful to do a prospective study of MRSA isolates from 
specific clinical syndromes that would be used in further studies in order to compare 
specific bacteriophage susceptibilities. 
Techniques such as Fluorescent Amplified-Fragment Length Polymorphism 
Analysis and staphylococcal chromosome cassette (SCC) typing may  
also be used to examine the genotypes of the different staphylococcal strains tested 
against the bacteriophages. In addition, it would be interesting to examine the possibility 
of being able to modify the bacteriophage in order to allow lysis of the previously 
resistant bacterial strains [69]. 
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